Table 2.

Treatment Delivery and Adherence.^*

Treatment Characteristic	Standard Management (N = 147)	ctDNA-Guided Management (N = 294)	Relative Risk (95% CI)
Adjuvant chemotherapy received — no. (%)
No	106 (72)	249 (85)
Yes	41 (28)	45 (15)	1.82 (1.25–2.65)
Chemotherapy regimen received — no./total no. (%)
Oxaliplatin-based doublet	4/41 (10)	28/45 (62)
Single-agent fluoropyrimidine	37/41 (90)	17/45 (38)	2.39 (1.62–3.52)
Median time from surgery to start of chemotherapy (IQR) — days	53 (49–61)	83 (76–89)
Median treatment duration (IQR) — wk	24 (21–24)	24 (19–24)
Reason for stopping chemotherapy — no./total no. (%)
Completion of planned treatment	32/41 (78)	38/45 (84)
Disease relapse	1/41 (2)	0/45 (0)
Patient request	1/41 (2)	1/45 (2)
Toxic effects	7/41 (17)	6/45 (13)
Percentage of full dose delivered
Mean	77±26	74±24
Median (IQR)	84 (64–100)	78 (56–100)

^*Plus–minus values are means ±SD. CI denotes confidence interval.